Skip to main content
Quest Diagnostics

Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-based Tests for Early Cancer Detection

Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-based Tests for Early Cancer Detection

Authors: Clarke CA, Mitchell BL, Alme E, Beer JP, Beer TM, Beidelschies MA, Hoyos J, Klein EA, Kuhn P, Krunic N, Lang K, Lee JSH, Lopez Ramos D, Morgenstern D, Putcha G, Quinn E, Raymond VM, Rubinstein WS, Sanchez SA, Serra RW, Stewart MD, Leiman LC

Citation: Clin Cancer Res. 2025 Apr 8. doi: 10.1158/1078-0432.CCR-24-4269. Online ahead of print.

Specialties: Oncology

Related content

Audio Podcast
Optimize Oncology Care with Clinical Pathways
Test FAQ
Haystack MRD Testing
Publication
Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.